Zhejiang Shengda Pharm
Zhejiang Shengda Bio-Pharm Co., Ltd. develops, produces, and sells food and feed additives for pharmaceutical, nutritional, food, and animal feed industry. It offers vitamins, such as biotin and folic acid; biological preservatives, including nisin, polylysine, and natamycin; and intermediate APIs. The company was incorporated in 1999 and is headquartered in Tiantai, China.
Market Cap & Net Worth: Zhejiang Shengda Pharm (603079)
Zhejiang Shengda Pharm (SHG:603079) has a market capitalization of $464.25 Million (CN¥3.41 Billion) as of March 18, 2026. Listed on the SHG stock exchange, this China-based company holds position #14280 globally and #3762 in its home market, demonstrating a 4.59% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Shengda Pharm's stock price CN¥18.02 by its total outstanding shares 189029624 (189.03 Million).
Zhejiang Shengda Pharm Market Cap History: 2017 to 2026
Zhejiang Shengda Pharm's market capitalization history from 2017 to 2026. Data shows growth from $653.81 Million to $464.25 Million (6.49% CAGR).
Zhejiang Shengda Pharm Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Shengda Pharm's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.42x
Zhejiang Shengda Pharm's market cap is 0.42 times its annual revenue
1.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
11.79x
Zhejiang Shengda Pharm's market cap is 11.79 times its annual earnings
10.29x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $653.81 Million | $508.56 Million | $72.61 Million | 1.29x | 9.00x |
| 2018 | $284.13 Million | $492.71 Million | $44.54 Million | 0.58x | 6.38x |
| 2019 | $704.16 Million | $519.15 Million | $47.03 Million | 1.36x | 14.97x |
| 2020 | $536.96 Million | $867.31 Million | $197.44 Million | 0.62x | 2.72x |
| 2021 | $438.56 Million | $789.73 Million | $75.76 Million | 0.56x | 5.79x |
| 2022 | $321.79 Million | $738.02 Million | $31.48 Million | 0.44x | 10.22x |
| 2023 | $375.37 Million | $727.41 Million | -$54.06 Million | 0.52x | N/A |
| 2024 | $347.03 Million | $827.40 Million | $29.42 Million | 0.42x | 11.79x |
Competitor Companies of 603079 by Market Capitalization
Companies near Zhejiang Shengda Pharm in the global market cap rankings as of March 18, 2026.
Key companies related to Zhejiang Shengda Pharm by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Zhejiang Shengda Pharm Historical Marketcap From 2017 to 2026
Between 2017 and today, Zhejiang Shengda Pharm's market cap moved from $653.81 Million to $ 464.25 Million, with a yearly change of 6.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥464.25 Million | +1.69% |
| 2025 | CN¥456.52 Million | +31.55% |
| 2024 | CN¥347.03 Million | -7.55% |
| 2023 | CN¥375.37 Million | +16.65% |
| 2022 | CN¥321.79 Million | -26.63% |
| 2021 | CN¥438.56 Million | -18.33% |
| 2020 | CN¥536.96 Million | -23.75% |
| 2019 | CN¥704.16 Million | +147.83% |
| 2018 | CN¥284.13 Million | -56.54% |
| 2017 | CN¥653.81 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Zhejiang Shengda Pharm was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $464.25 Million USD |
| MoneyControl | $464.25 Million USD |
| MarketWatch | $464.25 Million USD |
| marketcap.company | $464.25 Million USD |
| Reuters | $464.25 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.